| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 317 | 2019 |
| Discovery of piperlongumine as a potential novel lead for the development of senolytic agents Y Wang, J Chang, X Liu, X Zhang, S Zhang, X Zhang, D Zhou, G Zheng Aging (Albany NY) 8 (11), 2915, 2016 | 208 | 2016 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 144 | 2020 |
| Oxidation resistance 1 is a novel senolytic target X Zhang, S Zhang, X Liu, Y Wang, J Chang, X Zhang, SG Mackintosh, ... Aging cell 17 (4), e12780, 2018 | 90 | 2018 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 61 | 2020 |
| Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L X Zhang, D Thummuri, Y He, X Liu, P Zhang, D Zhou, G Zheng Chemical Communications 55 (98), 14765-14768, 2019 | 56 | 2019 |
| Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ... Journal of Hematology & Oncology 13 (1), 1-24, 2020 | 52 | 2020 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 47 | 2021 |
| Senolytic activity of piperlongumine analogues: synthesis and biological evaluation X Liu, Y Wang, X Zhang, Z Gao, S Zhang, P Shi, X Zhang, L Song, ... Bioorganic & medicinal chemistry 26 (14), 3925-3938, 2018 | 47 | 2018 |
| Assays and technologies for developing proteolysis targeting chimera degraders X Liu, X Zhang, D Lv, Y Yuan, G Zheng, D Zhou Future medicinal chemistry 12 (12), 1155-1179, 2020 | 41 | 2020 |
| Targeting anti-apoptotic BCL-2 family proteins for cancer treatment X Zhang, X Liu, D Zhou, G Zheng Future Medicinal Chemistry 12 (7), 563-565, 2020 | 30 | 2020 |
| Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood–brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2 X Liu, AF Kalogeropulou, S Domingos, N Makukhin, RS Nirujogi, F Singh, ... Journal of the American Chemical Society 144 (37), 16930-16952, 2022 | 25 | 2022 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of Medicinal Chemistry 64 (19), 14230-14246, 2021 | 21 | 2021 |
| A mild and efficient AgSbF6-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction S Gujarathi, X Liu, L Song, H Hendrickson, G Zheng Tetrahedron 70 (34), 5267-5273, 2014 | 20 | 2014 |
| PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors P Zhang, X Zhang, X Liu, S Khan, D Zhou, G Zheng Exploration of targeted anti-tumor therapy 1, 259, 2020 | 14 | 2020 |
| Piperlongumine conjugates induce targeted protein degradation J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ... Cell Chemical Biology 30 (2), 203-213. e17, 2023 | 7 | 2023 |
| Synthesis of (2R, 8′ S, 3′ E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol X Liu, S Gujarathi, X Zhang, L Shao, M Boerma, CM Compadre, ... Tetrahedron 72 (27-28), 4001-4006, 2016 | 7 | 2016 |
| Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production X Liu, Z Gao, Q Fu, L Song, P Zhang, X Zhang, H Hendrickson, PA Crooks, ... Bioorganic & medicinal chemistry 28 (11), 115498, 2020 | 6 | 2020 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun 12: 6896 D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... | 5 | 2021 |
| Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative X Liu, S Poddar, L Song, H Hendrickson, X Zhang, Y Yuan, D Zhou, ... ChemMedChem 15 (6), 506-516, 2020 | 5 | 2020 |
Guangrong ZhengProfessor, University of Florida在 cop.ufl.edu 的电子邮件经过验证
